Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors

scientific article published on 9 January 2014

Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/ML400466P
P8608Fatcat IDrelease_7fjkm7wjs5hunj5ru5rsj62w4q
P932PMC publication ID4027630
P698PubMed publication ID24900818

P50authorCharles JayneQ88797848
P2093author name stringPaul J Coleman
Joseph P Vacca
Ann E Weber
Robert Chase
Sathesh Bhat
Sony Agrawal
Srikanth Venkatraman
John A Howe
Sylvie Charron
Patrick Beaulieu
Joseph Romano
Unmesh Shah
Nigel J Liverton
Francisco Velázquez
Alexei Buevich
Samuel Chackalamannil
Yongxin Han
John A McCauley
Ian W Davies
Michael T Rudd
Zhuyan Guo
Helmi Zaghdane
Aileen Soriano
Benoit Bachand
Christiane Grisé-Bard
Kimberly Bush
Marie-Christine Brochu
Virender Aulakh
P2860cites workMolecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicaseQ27620480
Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease targetQ27659903
Diagnosis, management, and treatment of hepatitis C: an updateQ29619682
Telaprevir for previously untreated chronic hepatitis C virus infectionQ29619800
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
The global burden of hepatitis CQ29620138
Boceprevir for untreated chronic HCV genotype 1 infectionQ29620617
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsQ34276394
Direct-acting antiviral agents for hepatitis C virus infectionQ34321440
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorQ34423056
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United StatesQ40249402
P433issue3
P304page(s)264-269
P577publication date2014-01-09
P1433published inACS Medicinal Chemistry LettersQ2819061
P1476titleNovel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors
P478volume5

Reverse relations

cites work (P2860)
Q38714640Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor
Q38714156Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection
Q54210704Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy.
Q34411907MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Q26800050New era for management of chronic hepatitis C virus using direct antiviral agents: A review
Q38724091Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.

Search more.